MedTrace Logo

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes

NCT03214380 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 933

Last updated 2020-03-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).

Conditions

Interventions

DRUG

LY900014

Administered SC

DRUG

Insulin Lispro

Administered SC

DRUG

Insulin Glargine

Administered SC

DRUG

Insulin Degludec

Administered SC

DRUG

Metformin

Administered orally.

DRUG

SGLT2 inhibitor

Administered orally.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-14
Primary Completion
2018-08-14
Completion
2019-03-13
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Czechia
  • Germany
  • Hungary
  • India
  • Italy
  • Japan
  • Mexico
  • Puerto Rico
  • Russia
  • Slovakia
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03214380 on ClinicalTrials.gov